Skip to main content
Home COR-NTD

Main navigation

  • Research & outcomes
    • Go back
    • Research & outcomes
    • NTDConnectOR
  • Resources
    • Go back
    • Resources
    • Resources search
    • Publications
    • Tools
    • Meeting Reports
    • What are Neglected Tropical Diseases
    • NTD Toolbox
  • Funding Opportunities
  • Annual Meeting
  • Research Links
  • Partners
  • News & stories
    • Go back
    • News & stories
    • Blog
    • News articles
  • About us
    • Go back
    • About us
    • How we work
    • Funding
    • Secretariat (NTD-SC)
    • Get involved
    • Contact us
  1. Home
  2. Peer Reviewed Articles Search
  3. PoolTestR: An R package for estimating prevalence and regression modelling for molecular xenomonitoring and other applications with pooled samples
  4. PoolTestR: An R package for estimating prevalence and regression modelling for molecular xenomonitoring and other applications with pooled samples

PoolTestR: An R package for estimating prevalence and regression modelling for molecular xenomonitoring and other applications with pooled samples

1 November 2021
Angus McLure, Ben O'Neill, Helen Mayfield, Colleen Lau, Brady McPherson

Details

Resource type
Publication
DOI
10.1016/j.envsoft.2021.105158
Citation
Environmental Modelling & Software
8-2-2021
145
https://www.sciencedirect.com/science/article/abs/pii/S1364815221002012

Related studies

Added 31 March 2022

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Samoa

Australian National University (ANU),
Queensland University of Technology
Lymphatic filariasis
Research question

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis (LF) has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazoe (IDA) can be stopped with little risk of resurgence of transmission?
To develop an M&E strategy that enables Samoa’s LF elimination program to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission
What is the effectiveness of appropriately dosed IDA in clearing Mf from Mf positive people who (i) reported taking IDA in August 2018, and (ii) did not report recently taking IDA?

 

Coalition for Operational Research
on Neglected Tropical Diseases

Secretariat, Neglected Tropical Diseases Support Center

 

 

 

 

 

Privacy Policy        Terms and Conditions

 

This website for the Coalition for Operational Research on NTDs (COR-NTD) received financial support from the Bill & Melinda Gates Foundation and by the United States Agency for International Development through its Neglected Tropical Disease Program. This information provided on the website is not official  government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government or the U.K. Foreign, Commonwealth and Development Office or the U.K. Government.

A Remora website by Manta Ray Media